Modulight Bio
Boston
About Modulight Bio
Modulight Bio develops an optogenetic platform intended for the treatment of neurological disorders. The company’s technology uses optogenetics to modulate neuronal activity by targeting synaptic mechanisms. Its approach relies on endogenous cellular processes to adjust neural signaling with spatial and temporal precision. The platform is designed to address conditions associated with abnormal or excessive neuronal activation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $12.0M
- Funding stage: Seed
- Last round: Seed (Nov 2025)
- Website: modulight.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/modulight-bio-3885 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.